The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.


This site uses cookies for site interaction analysis with a purpose of service quality enhancing and uninterrupted site work. More details in Cookies Policy
18 October 2021

Darnitsa has bought to market 9 medical products in the third quarter of 2021

18 October 2021

The pharmaceutical company “Darnitsa” has brought to market 9 medical products for cardiological, neurological, gastroenterological diseases, as well as analgesic and antiseptic in the third quarter of 2021.

Pain is one of products the most common reasons for patients` requests to primary care physicians. For this reason, the company`s portfolio comprises several preparations for the treatment of pain with different etiologies in the third quarter.

In September the pharmaceutical company “Darnitsa” introduced a new branded line DARFEN® to provide treatment of pain and inflammation in adults and children. The DARFEN® brand offers medical products in the form of gel, tablets and suspension containing ibuprofen.

Another important and absolutely new preparation to prevent pain turned out to be Elptan, which is the only** eletriptan in Ukraine for the treatment of migraine attacks. This preparation has become an addition to the company`s prescription portfolio.

Andriy Obrizan, CEO of the pharmaceutical company “Darnitsa”:

“Darnitsa`s ambition goal” is to bring to market 23 new products by the end of the year. We are on the way to meet this goal, with 16 successful launches during the three quarters of 2021. It became possible due to the intensive efforts of the R&D team, the digitalization of a number of processes, and the transition to electronic pharmaceuticals workflows. The launch of new products on the market is expected to increase access to treatment for the population.

In particular, preparations for the treatment of peripheral arteries (Claudiex), depression and neuropathic pain (Simbia®), ulcerative disease of the stomach and 12-gut (Gastrotech®), as well as an antiseptic and disinfectant for external application condensation in a unique polypropylene vial (Sanidar®) were launched in the third quarter.


PJSC pharmaceutical company “Darnitsa” was founded in 1930 and this year it celebrates its 91st anniversary. Since 1998 “Darnitsa” has been the leader in Ukraine by the volume of production of medicines in kind. Strategic areas of portfolio development – cardiology, neurology, pain treatment. Darnitsa has brought to market 50 pharmaceutical brands during 2015-2020.

*The above-mentioned information is provided solely for dissemination in specialized publications aimed for medical institutions and physicians, as well as at conferences and seminars on medical topics

** on the date of publication 18 October, 2021.

Specialized edition for medical institutions and doctors.